Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Merck mulls PV program’s future while Takeda takes victory lap
Merck revealed the first look at data from a phase 2 trial of bomedemstat, while Takeda shared updated results from rusfertide's phase 3 study.
Darren Incorvaia
Dec 8, 2025 4:30pm
Merck's HIV combo matches Gilead's Biktarvy in phase 3 test
Nov 19, 2025 8:10am
ADC biotech raises $120M to seek best-in-class formula
Nov 17, 2025 8:00am
Merck pays $9.2B for owner of flu antiviral J&J rejected
Nov 14, 2025 8:25am
Promega wins FDA OK as Keytruda-Lenvima companion diagnostic
Nov 13, 2025 4:00am
Merck's PCSK9 drug mounts injectable-like cholesterol reductions
Nov 10, 2025 10:59am
